About us Technology Pipeline Partners News Career Contact We use Cookies We use scripts, such as cookies, to provide technical support for the site and third-party website tracking technology services to provide and continually improve our website and display advertisements based on your interests. By clicking the "Accept all" button, you agree to this. Your consent may be revoked at any time with effect for the future. By clicking on the "Show details" button, you can refuse to use the services for any or all purposes. Information about the type and scope of data processing, storage period and the service providers themselves can be found in our privacy policy. Show Details Accept all Welcome to Glycotope TARGETING TUMOR-SPECIFIC GLYCOSYLATION PATTERNS TO ENABLE ADVANCED THERAPIES We are Glycotope We are dedicated to improving the lives of cancer patients by enabling treatment options that go beyond today’s standard of care. With exceptional experience in glycobiology and therapeutic antibody development, our mission is to develop advanced biologics that facilitate novel approaches to cancer therapies. Setting new standards of tumor-specificity in antibody therapeutics About Us Learn More about Glycotope and our Leadership Team Learn more Technology Our proprietary technology platform enables the development of antibodies with unrivaled tumor-specificity Learn more Pipeline Our pipeline of antibody therapeutics includes in-house and partnered pre-clinical programs Learn more Partners We aim to continuously expand our collaborations with industry partners and academic centers to further exploit the unique potential of our technology Learn more News 15. November 2021 Glycotope Presents New Data on Carbohydrate-Dependent Antibodies and Fusion-Proteins at the 2021 Society for Immunotherapy of Cancer (SITC) Meeting Read Article 27. July 2021 Byondis and Glycotope Enter Platform Access Agreement for Discovery and Development of Antibodies Against Novel GlycoTargets Read Article 16. June 2021 Glycotope Poster Presentation at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting Read Article Read All Glycotope GmbH is project based co-funded by the European Fund for Regional Development (EFRE) Get in touch Glycotope GmbH Robert-Roessle-Str. 10 13125 Berlin Germany Tel.: +49 (0) 30 9489 2600 E-Mail: contact@glycotope.com Links About us Technology Pipeline Partners News Career Contact Privacy Policy Terms of Business / Imprint © Copyright 2021 GLYCOTOPE GmbH. All rights reserved.